Skip to main content
Log in

Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model

  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Summary

The potent and selective D2-agonist N-0437 [2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin] undergoes considerable first-pass metabolism after oral administration due to glucuronidation of the phenolic group. In an attempt to improve its bioavailability, seven ester prodrugs of N-0437 were synthesized, i. e. the acetyl-, propionyl-, isobutyryl-, pivaloyl-, 2-aminophenyl-, 2-methoxy-phenyl- and 2,4-dimethylphenylanalogues. In vivo activities were assessed by measuring contralateral turning after transdermal administration of N-0437 and its prodrugs to rats with unilateral 6-OHDA lesions of the nigrostriatal pathway. From time-effect curves the area under the curve for separate time intervals was taken as a measure of dopaminergic activity during that interval. It was found that slowly hydrolyzing prodrugs, which are known to show an improved duration of action after oral administration, are devoid of activity after transdermal application. The acetyl-, the propionyl-and the isobutyryl analogues, which are prodrugs with a relatively high hydrolysis rate, were found to have interesting and promising profiles following transdermal application.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Barry BW (1987) Transdermal drug delivery. In: Johnson P, Lloyd-Jones HG (eds) Drug delivery systems — fundamentals and techniques. Ellis Horwood, Chichester

    Google Scholar 

  • Bundgaard H (1984) Improved drug delivery by the prodrug approach. In: Müller BW (ed) Controlled drug delivery. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 179–196

    Google Scholar 

  • Bundgaard H (1985) Design of prodrugs: bioreversible derivatives for various functional groups and chemical entities. In: Bundgaard H (ed) Design of prodrugs. Elsevier, Amsterdam, pp 1–92

    Google Scholar 

  • Chan SY, Li Wan Po A (1989) Prodrugs for dermal delivery. Int J Pharm 55:1–16

    Article  CAS  Google Scholar 

  • Coleman RJ, Lange KW, Quinn NP, Loper AE, Bondi JV, Hichens M, Stahl SM, Marsden CD (1989) The antiparkinsonian actions and pharmacokinetics of transdermal (±)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Movement Disorders 4:129–138

    Article  CAS  PubMed  Google Scholar 

  • Den Daas I, Tepper PG, Horn AS (1990) Improvement of the oral bioavailability of the selective dopamine agonist N-4037 in rats: the in vitro and in vivo activity of eight ester prodrugs. Naunyn-Schmiedeberg's Arch Pharmacol 341:186–191

    Article  Google Scholar 

  • Gerding TK, Drenth BFH, De Zeeuw RA, Tepper PG, Horn AS (1990) The metabolic fate of the dopamine agonist 2-(N-propylN-2-hienylethylamino)-5-hydroxytetralin (N-0437) in rats after intravenous and oral administration. II Isolation and identification of metabolites. Xenobiotica 20:525–536

    CAS  PubMed  Google Scholar 

  • Hadgraft J (1985) Prodrugs and skin absorption. In: Bundgaard H (ed) Design of prodrugs. Elsevier, Amsterdam, pp 271–289

    Google Scholar 

  • Higuchi WI, Yu C-D (1983) Prodrugs in transdermal delivery. In: Kydonieus AF, Berner B (eds) Transdermal delivery of drugs. vol 3. CRC Press, Boca Raton, pp 44–83

    Google Scholar 

  • König JFR, Klippel RA (1963) The rat brain: a stereotaxic atlas of the forebrain and lower parts of the brainstem. Williams and Wilkins, Baltimore

    Google Scholar 

  • Löschmann P-A, Chong PN, Nomoto M, Tepper PG, Horn AS, Jenner P, Marsden CD (1989) Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. Eur J Pharmacol 166:373–380

    PubMed  Google Scholar 

  • Martin YC (1978) Calculation of the physical properties of compounds. In: Quantitative drug design, a critical introduction. Dekker, New York, pp 61–95

    Google Scholar 

  • Monkhouse DC, Juq AS (1988) Transdermal drug delivery — problems and promises. Drug Dev Ind Pharm 14:183–209

    CAS  Google Scholar 

  • Mouradian MM, Juncos JC, Fabbrini G, Chase TN (1987) Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 22:475–479

    Article  CAS  PubMed  Google Scholar 

  • Pflegel P, Dittgen M (1987) Arzneimittel and Organismus (VI) —transdermale therapeutische Systeme. Pharmazie 42:799–809

    CAS  PubMed  Google Scholar 

  • Rinne UK (1989) Early dopamine agonist therapy in Parkinson's disease. Movement Disorders 4:S86-S94

    Article  PubMed  Google Scholar 

  • Rupniak NMJ, Tye SJ, Jennings CA, Loper AE, Bondi JV, Hichens M, Hand E, Iversen SD, Stahl SM (1989) Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology 39:329–335

    CAS  PubMed  Google Scholar 

  • Sloan KB (1989) Prodrugs for dermal delivery. Adv Drug Delivery Rev 3:67–101

    Article  CAS  Google Scholar 

  • Timmerman W, Westerink BHC, De Vries JB, Tepper PG, Horn AS (1989) Microdialysis and striatal dopamine release: stereoselective actions of the enantiomers of N-0437. Eur J Pharmacol 162:143–150

    Article  CAS  PubMed  Google Scholar 

  • Ungerstedt U, Arbuthnott AW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485–493

    Article  CAS  PubMed  Google Scholar 

  • Van der Weide J, De Vries JB, Tepper PG, Horn AS (1987) In vitro binding of the very potent and selective D-2 dopamine agonist [3H]N-0437 to calf caudate membranes. Eur J Pharmacol 134:211–219

    PubMed  Google Scholar 

  • Wooten GF (1988) Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neur 24:363–365

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Deceased January 2, 1990

Send offprint requests to I. den Daas at the above address

Rights and permissions

Reprints and permissions

About this article

Cite this article

den Daas, I., Tepper, P.G., Rollema, H. et al. Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model. Naunyn-Schmiedeberg's Arch Pharmacol 342, 655–659 (1990). https://doi.org/10.1007/BF00175708

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00175708

Key words

Navigation